- $30.46bn
- $30.47bn
- $3.62bn
- 97
- 14
- 55
- 55
Annual cashflow statement for DexCom, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 101 | 494 | 155 | 341 | 542 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 159 | 213 | 323 | 167 | 72.8 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 6.1 | -20.8 | -132 | 26.7 | 3.2 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 315 | 476 | 443 | 670 | 749 |
| Capital Expenditures | -180 | -199 | -389 | -365 | -237 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -835 | -819 | 173 | -157 | -271 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -1,015 | -1,018 | -216 | -522 | -507 |
| Financing Cash Flow Items | -1.2 | -9.4 | -9.9 | -17.3 | -99.8 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 10.7 | 912 | 10.4 | -553 | -319 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -691 | 372 | 235 | -410 | -75.8 |